Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P40261

UPID:
NNMT_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P40261

BACKGROUND:
Nicotinamide N-methyltransferase (NNMT) is central to regulating the methylation landscape of cells, consuming S-adenosyl-L-methionine to limit its availability for other methyltransferases. This enzyme is instrumental in the hypomethylation of repressive chromatin marks, thereby influencing genome-wide transcriptional changes. NNMT's function extends to metabolic regulation, affecting adipose tissue energy expenditure and liver functions.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Nicotinamide N-methyltransferase unveils its potential as a target in developing therapeutic interventions for metabolic diseases and conditions associated with epigenetic dysregulation. Its role in cellular methylation and metabolism highlights its significance in novel drug discovery efforts.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.